Key result
Ivabradine rapidly resolves drug-resistant ectopic atrial tachycardia in pediatric CPVT.
Case Report (n=1)
No
Ivabradine may serve as an effective therapeutic option to resolve drug-resistant ectopic atrial tachycardia in selected patients with catecholaminergic polymorphic ventricular tachycardia.
May warrant consideration for refractory atrial tachycardia in pediatric CPVT; leaves open the need for prospective validation before adoption.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare hereditary arrhythmia characterized by adrenergic stress-induced polymorphic ventricular tachycardia. Supraventricular arrhythmias, including ectopic atrial tachycardia (EAT), may occur; however, their management in patients with CPVT has not been well established. This case report presents an 11-year-old boy with CPVT who developed drug-resistant EAT. Despite treatment with beta-blockers, flecainide, and sotalol, EAT persisted. Ivabradine therapy was initiated, resolving the arrhythmia within hours. This unique case highlights the potential role of ivabradine as a therapeutic option in carefully selected patients. Multicenter studies are required to further evaluate the potential role of ivabradine alongside beta-blockers in the management of CPVT-related arrhythmias.
No takes yet. Share an insight, caveat, or question.
Küçüker et al. (2026) conducted a case report in Catecholaminergic polymorphic ventricular tachycardia (CPVT) with drug-resistant ectopic atrial tachycardia (EAT) (n=1). Ivabradine was evaluated on Resolution of ectopic atrial tachycardia. Ivabradine therapy resolved drug-resistant ectopic atrial tachycardia within hours in an 11-year-old boy with catecholaminergic polymorphic ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: